Financials VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-12 pm EST			5-day change	1st Jan Change
0.3756 ^USD	-7.28%		+1.51%	-88.79%

Nov. 06	VYNE Therapeutics Q3 net loss narrows, strategic review ongoing	RE
Nov. 06	VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Projected Income Statement: VYNE Therapeutics Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	20.99	14.76	0.477	0.424	0.501	0.4	0.2333	-
Change	-	-29.71%	-96.77%	-11.11%	18.16%	-20.16%	-41.67%	-
EBITDA ¹	-	-	-	-29.26	-43.63	-44	-50.7	-57.7
Change	-	-	-	-	-49.13%	-0.84%	-15.23%	-13.81%
EBIT ¹	-252.5	-68.03	-34.3	-29.26	-43.64	-32.5	-44.7	-66.35
Change	-	73.06%	49.59%	14.69%	-49.15%	25.52%	-37.54%	-48.43%
Interest Paid	-4.39	-5.61	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-255.8	-73.78	-33.93	-27.87	-39.8	-41.1	-50.25	-66.25
Change	-	71.16%	54.01%	17.86%	-42.81%	-3.26%	-22.26%	-31.84%
Net income ¹	-255.6	-73.33	-23.21	-28.45	-39.83	-29.4	-44.13	-66.25
Change	-	71.31%	68.35%	-22.59%	-40%	26.19%	-50.11%	-50.11%
Announcement Date	3/4/21	3/17/22	3/9/23	2/29/24	3/6/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4
Net sales ¹	4.286	4.119	4.258	4.086	2.292	0.178	0.126	0.167	0.006	0.099	0.135	0.114	0.076	0.098	0.198	0.121	0.084	0.202	0.069	0.169	0.2	0.2	0.2	0.2	0.2
Change	-	-3.9%	3.37%	-4.04%	-43.91%	-92.23%	-29.21%	32.54%	-96.41%	1,550%	36.36%	-15.56%	-33.33%	28.95%	102.04%	-38.89%	-30.58%	140.48%	-65.84%	144.93%	18.34%	0%	0%	0%	0%
EBITDA ¹	-	-	-	-	-	-	-	-	-	-	-	-6.234	-6.832	-7.38	-10.4	-13.09	-12.77	-9.191	-7.536	-	-12.6	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-9.59%	-8.02%	-40.87%	-25.92%	2.48%	28%	18.01%	-	-	-	-	-	-
EBIT ¹	-21.99	-19.43	-16.88	-17.78	-12.04	-8.691	-8.287	-9.333	-7.984	-5.875	-10.32	-	-	-	-	-	-12.77	-9.197	-7.542	-7.792	-7.9	-8.1	-8.3	-8.4	-8.6
Change	-	11.63%	13.13%	-5.31%	32.25%	27.84%	4.65%	-12.62%	14.45%	26.42%	-75.63%	-	-	-	-	-	-	27.98%	17.99%	-3.31%	-1.39%	-2.53%	-2.47%	-1.2%	-2.38%
Charge d'intérêts	-1.161	-1.119	-1.074	-3.474	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-23.18	-20.55	-19.92	-21.28	-12.02	-8.694	-8.235	-9.255	-7.748	-5.612	-10.04	-6.071	-6.152	-	-9.395	-12.16	-12.01	-8.603	-5.747	-7.426	-12.5	-	-	-	-
Change	-	11.35%	3.05%	-6.83%	43.54%	27.66%	5.28%	-12.39%	16.28%	27.57%	-78.87%	39.52%	-1.33%	-	-	-29.4%	1.21%	28.37%	33.2%	-29.22%	-68.33%	-	-	-	-
Net income ¹	-23.18	-20.55	-19.92	-21.28	-11.57	4.67	-8.476	-9.459	-9.945	-5.622	-10.06	-6.584	-6.188	-6.249	-9.406	-12.16	-12.02	-8.611	-5.755	-7.28	-7.6	-7.7	-7.9	-8.1	-8.2
Change	-	11.35%	3.05%	-6.83%	45.64%	140.36%	-281.5%	-11.6%	-5.14%	43.47%	-78.9%	34.54%	6.01%	-0.99%	-50.52%	-29.25%	1.11%	28.37%	33.17%	-26.5%	-4.4%	-1.32%	-2.6%	-2.53%	-1.23%
Announcement Date	3/4/21	5/6/21	8/12/21	11/10/21	3/17/22	5/12/22	8/12/22	11/10/22	3/9/23	5/11/23	8/14/23	11/13/23	2/29/24	5/9/24	8/14/24	11/7/24	3/6/25	5/8/25	8/14/25	11/6/25	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: VYNE Therapeutics Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Announcement Date	3/4/21	3/17/22	3/9/23	2/29/24	3/6/25	-	-	-

Estimates

Cash Flow Forecast: VYNE Therapeutics Inc.

Fiscal Period: December	2020	2021	2025	2026	2027
CAPEX ¹	0.113	-	5	5	5
Change	-	-	-	0%	0%
Free Cash Flow (FCF) ¹	-137.2	-56.37	-44.4	-55.7	-80.9
Change	-	58.91%	-	-25.45%	-45.24%
Announcement Date	3/4/21	3/17/22	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: VYNE Therapeutics Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-	-	-	-	-6,900.47%	-8,709.18%	-11,000%	-21,728.88%	-
EBIT Margin (%)	-	-1,203%	-461.08%	-7,189.73%	-6,900.47%	-8,709.98%	-8,125%	-19,157.42%	-
EBT Margin (%)	-	-1,218.63%	-500.01%	-7,113.63%	-6,573.58%	-7,944.71%	-10,275%	-21,536.02%	-
Net margin (%)	-	-1,217.4%	-496.98%	-4,865.83%	-6,710.38%	-7,950.9%	-7,350%	-18,914.55%	-
FCF margin (%)	-	-653.53%	-382.02%	-	-	-	-11,100%	-23,871.77%	-
FCF / Net Income (%)	-	53.68%	76.87%	-	-	-	151.02%	126.21%	122.11%
Profitability
ROA	-64.82%	-69.52%	-52.89%	-39.77%	-26.42%	-33.14%	-	-	-
ROE	-173.43%	-928.19%	-170.28%	-84.81%	-46.4%	-56.54%	-	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	0.54%	-	-	-	-	1,250%	2,142.89%	-
CAPEX / EBITDA (%)	-	-	-	-	-	-	-11.36%	-9.86%	-8.67%
CAPEX / FCF (%)	-	-0.08%	-	-	-	-	-11.26%	-8.98%	-6.18%
Items per share
Cash flow per share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
EPS ¹	-	-141.8	-25.56	-7.28	-2.78	-0.93	-0.69	-0.66	-0.64
Change	-	-	81.98%	71.52%	61.81%	66.55%	25.81%	4.35%	3.03%
Nbr of stocks (in thousands)	-	2,332	2,973	3,224	13,957	14,751	33,286	33,286	33,286
Announcement Date	-	3/4/21	3/17/22	3/9/23	2/29/24	3/6/25	-	-	-